Deutsche Bank AG Has $782,000 Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Deutsche Bank AG is a multinational investment bank and financial services company headquartered in Frankfurt, Germany. The company has a significant presence in various global markets, including North America, Europe, Asia-Pacific, and Latin America.

TG Therapeutics, Inc. NASDAQTGTX is a biopharmaceutical company based in New York City, United States. The company focuses on the development and commercialization of novel therapies for cancer and autoimmune diseases. TG Therapeutics has a diverse portfolio of clinical-stage programs, including its flagship product, T-VEC, which is being developed for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

In the 3rd quarter of 2021, Deutsche Bank AG lessened its stake in TG Therapeutics, Inc. NASDAQTGTX by 2.5%. The firm owned 93,537 shares of the biopharmaceutical company's stock after selling 2,411 shares during the quarter. This represents a decrease in ownership from 96,088 shares to 93,537 shares.

It is important to note that Deutsche Bank AG's stake in TG Therapeutics, Inc. NASDAQTGTX is relatively small compared to other investors in the company. As of the most recent disclosure with the Securities & Exchange Commission, TG Therapeutics has over 100 million shares outstanding, and its market capitalization is approximately $2.5 billion.

Overall, Deutsche Bank AG's decision to lessen its stake in TG Therapeutics, Inc. NASDAQTGTX reflects the company's ongoing evaluation of its investment portfolio and its commitment to supporting innovative biopharmaceutical companies like TG Therapeutics in their mission to develop new treatments for patients with cancer and autoimmune diseases.